Form 4/A for MNKD MANNKIND CORP
Accepted 2022-08-24 00:00:00 ET · period of report 2022-02-28 · accession 0001209191-22-047428 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-08-24 | 2022-02-28 | MNKD | Galindo Alejandro | EVP Endocrine Business Unit | A - Grant | $2.71 | +36.9K | 576.7K | +7% | +$100.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock,$.01 par value | 2022-02-28 | A | A | 36,900 | $2.71 | 576,690 | D | — | — |